Search Results - Xiaomin Wan

Cost-Effectiveness Analysis of Hepatic Arterial Infusion Chemotherapy of Infusional Fluorouracil, Leucovorin, and Oxaliplatin Versus Transarterial Chemoembolization in Patients Wit... by Haixia Zhang, Xiaohui Zeng, Ye Peng, Chongqing Tan, Xiaomin Wan

Connect to this object online.

Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis by Xiaohui Zeng, Qiao Liu, Chongqing Tan, Xiaomin Wan, Yunhua Wang, Xiaowei Ma

Connect to this object online.

Dynamic zero-COVID strategy in controlling COVID-19 in Shanghai, China: A cost-effectiveness analysis by Chongqing Tan, Xia Luo, Zhen Zhou, Xiaohui Zeng, Xiaomin Wan, Lidan Yi, Qiao Liu

Connect to this object online.

Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China by Kehui Meng, Heng Xiang, Meiyu Wu, Ouyang Xie, Andong Li, Chongqing Tan, Xiaomin Wan

Connect to this object online.

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China by Dongchu Zhou, Xia Luo, Zhen Zhou, Xiaohui Zeng, Xiaomin Wan, Chongqing Tan, Qiao Liu

Connect to this object online.

Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma by Si Ni Li, Xiaomin Wan, Liu Bao Peng, Ya Min Li, Jian He Li

Connect to this object online.

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer by Meiyu Wu, Meiyu Wu, Shuxia Qin, Shuxia Qin, Liting Wang, Liting Wang, Chongqing Tan, Chongqing Tan, Ye Peng, Ye Peng, Xiaohui Zeng, Xia Luo, Xia Luo, Lidan Yi, Lidan Yi, Xiaomin Wan, Xiaomin Wan

Connect to this object online.

Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review by Meiyu Wu, Meiyu Wu, Shuxia Qin, Shuxia Qin, Liting Wang, Liting Wang, Chongqing Tan, Chongqing Tan, Ye Peng, Ye Peng, Xiaohui Zeng, Xia Luo, Xia Luo, Lidan Yi, Lidan Yi, Xiaomin Wan, Xiaomin Wan

Connect to this object online.

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis by Qiao Liu, Zhen Zhou, Xia Luo, Lidan Yi, Liubao Peng, Xiaomin Wan, Chongqing Tan, Xiaohui Zeng

Connect to this object online.

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50% by Qiao Liu, Zhen Zhou, Xia Luo, Lidan Yi, Liubao Peng, Xiaomin Wan, Chongqing Tan, Xiaohui Zeng

Connect to this object online.

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell L... by Xia Luo, Qiao Liu, Zhen Zhou, Lidan Yi, Liubao Peng, Xiaomin Wan, Xiaohui Zeng, Chongqing Tan, Sini Li

Connect to this object online.

Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study by Shuxia Qin, Xuehong Wang, Sini Li, Sini Li, Chongqing Tan, Xiaohui Zeng, Meiyu Wu, Ye Peng, Liting Wang, Xiaomin Wan

Connect to this object online.

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer by Xiaomin Wan, Xiaohui Zeng, Liubao Peng, Ye Peng, Qiao Liu, Lidan Yi, Xia Luo, Qijian Deng, Qijian Deng, Chongqing Tan

Connect to this object online.

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis by Ye Peng, Xiaohui Zeng, Liubao Peng, Qiao Liu, Lidan Yi, Xia Luo, Sini Li, Liting Wang, Shuxia Qin, Xiaomin Wan, Chongqing Tan

Connect to this object online.